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AbstrACt
Introduction Despite their young age and relatively short 
duration of disease, younger adults with type 2 diabetes 
(T2D) already have diastolic dysfunction and may be at risk 
of incipient heart failure. Whether weight loss or exercise 
training improve cardiac dysfunction in people with T2D 
remains to be established.
Methods and analysis Prospective, randomised, open-
label, blind endpoint trial. The primary aim of the study 
is to determine if diastolic function can be improved by 
either a meal replacement plan or a supervised exercise 
programme, compared with guideline-directed care. 
A total of 90 obese participants with T2D (aged 18–65 
years), diabetes duration <12 years and not on insulin 
treatment will be randomised to either guideline-directed 
clinical care with lifestyle coaching, a low-energy 
meal replacement diet (average ≈810 kcal/day) or a 
supervised exercise programme for 12 weeks. Participants 
undergo glycometabolic profiling, cardiopulmonary 
exercise testing, echocardiography and MRI scanning to 
assesses cardiac structure and function and dual-energy 
X-ray absorptiometry scanning for body composition. 
Key secondary aims are to assess the effects of the 
interventions on glycaemic control and insulin resistance, 
exercise capacity, blood pressure, changes in body 
composition and association of favourable cardiac 
remodelling with improvements in weight loss, exercise 
capacity and glycometabolic control.
Ethics and dissemination The study has full ethical 
approval, and data collection was completed in August 
2018. The study results will be submitted for publication 
within 6 months of completion.
trial registration number NCT02590822; Pre-results.
bACkground   
Recent estimates suggest there are currently 
425 million people with type 2 diabetes 
mellitus (T2D) globally.1 The dramatic rise 
in the levels of obesity and sedentary lifestyles 
in younger age groups has resulted in up to 
a 10-fold increase in the prevalence of T2D 
in younger adults.2 Whereas T2D was once 
a rarity in young people, increasingly we are 
seeing the condition diagnosed in children, 
adolescents and adults under the age of 30 
years.3 4 The onset of T2D in younger people 
represents an extreme phenotype that magni-
fies the disease profile observed in older 
adults. This is of clinical significance and 
represents an important public health issue.
strengths and limitations of this study
 ► There are few published studies demonstrating the 
beneficial effects of weight loss or exercise pro-
grammes on cardiac remodelling and function in 
people with type 2 diabetes (T2D).
 ► The Diabetes Interventional Assessment of Slimming 
or Training tO Lessen Inconspicuous Cardiovascular 
Dysfunction study will comprehensively describe 
changes in cardiac structure and function in younger 
obese people with T2D treated with either a low-en-
ergy meal replacement diet or exercise programme.
 ► This is a proof-of-efficacy study, and therefore, 
effects on clinical outcomes is not planned with a 
short duration of follow-up.
 ► Only patients who are able to exercise and willing to 
undertake the meal replacement plan are eligible, 
and we have limited our inclusion to younger adults 
(<65 years) with a maximum duration of diabetes 
of 12 years, so the results will not necessarily be 
generalisable to all people with T2D.
 ► Recruitment to the study ended in August 2018.
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The most deleterious consequence of developing T2D 
is a substantially elevated risk of cardiovascular disease 
(CVD), a feature that is magnified in younger adults. For 
example, the 20-year mortality rate in younger adults with 
T2D is as high as 11%, the majority from CVD.5 Further-
more, 48% of young adults with obesity at 22 years of age 
experience some form of CVD or early mortality with a 
life expectancy of 55 years.6 This is a rapidly emerging 
clinical pattern, where the mechanisms driving the high 
disease burden in younger adults with T2D, and potential 
therapeutic strategies, have not been fully elucidated.
While the risk of developing coronary artery disease and 
stroke are well recognised, the association of diabetes with 
heart failure (HF) has received less attention.7 Diabetes is 
an independent risk factor for the development of HF.8–10 
In the 2015–2016 UK National Diabetes Audit, there were 
115 695 emergency admissions for patients with diabetes 
and HF (32.5% of all HF admissions) despite people with 
diabetes representing only 8% of the population. Impor-
tantly, as many as half of all patients in the community 
with HF are asymptomatic.11 There is a high prevalence 
of people with diabetes with both common forms of HF: 
reduced systolic left ventricular (LV) function and HF 
with preserved ejection fraction (which represents up to 
50% of cases in the community).12
diabetic cardiomyopathy: the precursor to clinical HF
Diabetic cardiomyopathy is defined as myocardial disease 
in patients with diabetes, not attributable to hypertension, 
coronary artery disease or other cardiac disease.13 The 
pathophysiology of diabetic cardiomyopathy is complex, 
involving metabolic, vascular, inflammatory, epigenetic 
and neuroendocrine mechanisms. Diastolic (relaxation/
filling) dysfunction and concentric LV remodelling typify 
most cases, with a prevalence of up to 75% in adults with 
T2D.14–16 Multiple parameters have been associated with 
diastolic dysfunction including glycated haemoglobin 
(HbA1c) level,17 age,18 aortic stiffness,19 duration of 
diabetes,19 microvascular dysfunction20 and myocardial 
triglyceride content.21–23
Pilot data: cardiovascular dysfunction in younger adults with 
t2d
A pilot Medical Research Council (MRC)-funded study 
investigating the biochemical and cardiac abnormalities 
associated with T2D in younger adults (18–40 years) was 
conducted by our group.19 Twenty young adults with diag-
nosed T2D, 20 age-matched metabolically healthy obese 
and 10 lean controls were recruited. Cardiac structure 
and function were assessed by tagged cardiac MRI (CMRI) 
and myocardial perfusion and scarring were assessed with 
contrast-enhanced CMRI. There were elevated inflamma-
tory markers (high sensitivity C-reactive protein (hsCRP), 
interleukin-6 and 10 and tumour necrosis factor-alpha), 
reduced adiponectin and a strong trend for concentric 
remodelling (increased LV mass/volume) in both the 
T2D and obese controls versus the lean controls. The 
most striking finding was evidence of greater diastolic 
dysfunction in T2D compared with both the obese and 
lean controls.19 Specifically, peak early diastolic strain rate 
(PEDSR) had an average value of  1.3
1
s   in  the patients 
with T2D, which was 20% lower than the obese controls 
and 30% lower compared with the lean controls. There 
was also a strong trend towards reduced systolic strain in 
T2D (−21%) compared with both control groups (−23%, 
p=0.08), which suggests these patients may be at risk of 
incipient systolic dysfunction and are indeed already at 
the threshold of early diabetic cardiomyopathy.
These results were consistent with a larger echocardio-
graphic study in adolescents with diabetes compared with 
lean and obese controls.24 There is a growing body of 
evidence that preclinical diastolic dysfunction is already 
manifest in younger adults with T2D, despite their rela-
tively young age and short duration of T2D. This is of 
high clinical relevance and suggests that the high risk of 
CVD observed in T2D may be linked to diastolic dysfunc-
tion, predisposing these patients to HF, in advance of 
overt systolic compromise.14 15 Therefore, therapeutic 
strategies that target both glycaemic control and diastolic 
cardiac function are highly desirable in younger adults 
with T2D to prevent the development of HF.
Interventions to reverse diastolic dysfunction in t2d
Proof that T2D is a reversible condition has been firmly 
established in patients undergoing bariatric surgery25 26 
and more recently with intensive primary care-led weight 
management in the Diabetes Remission Clinical Trial 
(DiRECT) trial.27 The extent of weight loss is strongly 
linked to reversal of T2D (with a diabetes remission 
rate of 7% with weight loss <5 kg vs 86% with weight 
loss ≥15 kg),27 as is good glycaemic control before 
surgery.26 Insulin use, diabetes duration and high HbA1c 
levels are associated with reduced likelihood of reversal.26 
These studies, however, have not assessed changes in 
cardiovascular function.
Low and very low energy diets (VLEDs)
The phenotypic characteristics of T2D (excess body 
weight, ectopic fat deposition and insulin resistance) are 
largely normalised through VLEDs (typically <800 kcal/
day) via a meal replacement approach. Many of the 
metabolic responses mimic adaptions following bariatric 
surgery.28 A proof-of-concept study showed that just 8 
weeks of 510kcal/day diet via this approach resulted in 
normalisation of fasting glucose, hepatic glucose produc-
tion and hepatic triglyceride content with substantial 
improvements in glucose disposal rates.29 30 In a larger 
(n=298) recent trial of a low-energy total diet replace-
ment programme (825–853 kcal/day over 3–5 months) 
versus guideline-driven best practice, diabetes remission 
was achieved in almost half (46%) of those who received 
the diet (mean weight loss 10 kg) compared with only 
4% in the comparator group (mean weight loss 1 kg).27 
Many of these improvements are seen within 1 week. The 
majority of T2D individuals are also found to lose 50% 
of excess body weight within 8–12 weeks of VLED.29 30 
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In a self-reported study of dietary induced weight loss, 
diabetes reversal was positively associated with the magni-
tude of weight loss and inversely with diabetes duration 
(being lowest in those with diabetes >8 years).31
In obese subjects without T2D, sustained weight loss, 
either with diet or after surgery, has resulted in favour-
able reductions in cardiovascular MRI (CMRI) measured 
LV mass, volumes, arterial stiffness and diastolic func-
tion.32 Improved diastolic function following weight loss 
in obesity has been associated with improved energetics33 
and with reduced myocardial triglyceride content.34 In 
patients with insulin-treated T2D, a 471 kcal/day VLED 
has also been shown to reduce myocardial steatosis 
(0.88%±0.12% to 0.64±0.14%, p=0.02) in a small (n=12) 
single-group study and was associated with improved 
diastolic filling on CMR.35 Interestingly, a brief report 
from the same group suggests that in the first few days 
after commencing a VLED there may actually be an 
increase in steatosis and reduced diastolic filling.36
There is a wide range of research incorporating the 
use of LED/VLED; however, the definition in practice 
is somewhat blurred, with VLED often much lower than 
800 kcal/day. It is recognised that weight loss results 
from LED around 800 kcal/day are similar to those 
with lower energy intakes but with fewer adverse effects 
including limited loss of lean mass.37 For this study, we 
therefore chose a diet based on an intake of ≈810 kcal/
day (Cambridge Weight Plan).
Exercise programmes
Physical activity has consistently been associated with 
a reduced risk of T2D and a reduced risk of premature 
mortality and CVD mortality in those with diagnosed 
T2D.38 39 Interventional studies have demonstrated 
a strong causal link between exercise training and 
glycaemic control in those with T2D. Indeed, exercise 
training has consistently been found to lower HbA1c by 
0.6%–0.7%, with greater effects seen with higher volumes 
of exercise.40 41 Importantly, these substantial benefits 
are maintained when exercise training does not result 
in weight loss.40 41 This is consistent with experimental 
studies that have elucidated key insulin-dependent and 
insulin-independent pathways linking physical activity 
to improved glucose regulation that do not act through 
adiposity.42 43 Therefore, physical activity is an effective 
therapy for promoting metabolic health and glucose 
regulation independent of body weight. While the bene-
fits of exercise training on glycaemic control are well 
established, the effects on diastolic function are less well 
known, primarily due to insufficient data, differences in 
measurement and poor study design. However, encour-
aging data are starting to emerge in those with obesity. 
For example, an 8-week exercise training programme 
in obese men improved diastolic function to levels seen 
in lean controls, despite no weight loss.44 Similarly, just 
4 weeks of exercise training has been shown to improve 
diastolic function in those with HF with similar improve-
ments also observed in a matched cohort without HF.45
Only two studies that we are aware of have been 
conducted specifically in people with T2D assessing 
the effects of exercise training on diastolic function. A 
small pilot study found improvements in diastolic func-
tion following 3 months of aerobic exercise training in 
those with T2D (although tissue Doppler imaging was 
not performed, and the randomised groups were not 
well matched),46 while another study found no overall 
effect.47 However, in the latter study, a post hoc anal-
ysis revealed that change in moderate-intensity phys-
ical activity was significantly associated with change in 
myocardial strain rate, although it is unclear whether 
this was systolic, diastolic or both.47 This mirrors the 
wider evidence where light-to-moderate aerobic exercise 
training has repeatedly been demonstrated to improve 
diastolic function across a number of groups.44 46 The 
effectiveness of vigorous-intensity exercise or combined 
aerobic and resistance training is less well established, 
with at least one study showing the latter approach is 
not effective.48 Given this evidence base, it is important 
the efficacy of aerobic exercise training is investigated 
further, including in younger adults with T2D.
Aims
The primary aim of the study is to determine if diastolic 
function can be improved by either a meal replacement 
low energy diet plan (MRP) or a supervised exercise 
programme, compared with guideline-directed care. 
Key secondary aims are to assess the effects of the inter-
ventions on glycaemic control and insulin resistance, 
exercise capacity, blood pressure, changes in body compo-
sition and association of favourable cardiac remodelling 
with improvements in weight loss, exercise capacity and 
glycometabolic control. The primary hypothesis is that 
an MRP and/or exercise will improve diastolic function 
when compared with standard care alone.
MEtHods And AnAlysIs
study design
This is a single-centre study, which will comprise a baseline 
and follow-up analysis of a three-arm 12-week prospec-
tive, randomised, open-label, blinded end point trial of 
a low-energy MRP and an exercise programme compared 
with standard care in young adults with T2D.
study population
Potential participants will be identified from both primary 
and secondary care in Leicester, Leicestershire and 
Rutland using electronic databases and with support from 
the National Institute for Health Research East Midlands 
Local Clinical Research Network. At-risk groups, such as 
slimming clubs/weight watchers, will also be contacted 
within the local community. All patients meeting the 
inclusion and exclusion criteria (table 1) will proceed 
to the baseline visit and the study. We describe our age 
range as ‘younger’ and not specifically as ‘young’ as in 
developed countries, diabetes prevalence peaks between 
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the ages of 75 years and 79 years.49 In this study, the inclu-
sion of people with T2D <65 years therefore classifies 
the cohort as younger relative to the general UK popu-
lation of people with T2D. A Consolidated Standards of 
Reporting Trials (CONSORT) diagram will be produced, 
which will include the number of patients: approached, 
consenting, meeting eligibility criteria, randomised and 
completing each phase of the study.
study visits
An outline of study visits and measures taken is shown in 
figure 1. Participants are offered £50 compensation for 
each of the three assessment visits completed (baseline, 
4-week and 12-week visits).
Baseline visit and randomisation
A study clinician will check eligibility of the potential 
participant and obtain written informed consent. Base-
line data including patients’ demographics, medical 
history and anthropometric measures (height, weight, 
body mass index, blood pressure and waist and hip 
measurements) will be collected. Total fat mass and fat 
free mass will be assessed by a dual-energy X-ray absorp-
tiometry (DEXA) scan (Lunar iDEXA, General Electric 
Healthcare, Bedford, UK). Habitual physical activity 
and sedentary time will be assessed using objective (Acti-
Graph GT3X+ accelerometer, USA) and subjective (phys-
ical activity questionnaires) measures. A fasting blood 
sample will also be taken to check a range of measures 
including a biochemical profile for diabetes control, liver 
and kidney function and lipid profile, together with other 
measures of endocrine function (eg, fasting insulin, 
C-peptide and thyroid function tests) and inflammation. 
Insulin resistance will be estimated using the homeo-
static model assessment-insulin resistance method50 
and the triglyceride/high-density lipoprotein (HDL) 
ratio.51 Additional blood samples will be collected for the 
storage of plasma and serum for future metabolomic and 
proteomic investigation.
Participants will undergo comprehensive CMRI scan-
ning and transthoracic echocardiography performed 
at baseline as outlined below. They will then undergo a 
maximum symptom-limited incremental exercise test on 
a stationary electromagnetically braked cycle ergometer 
(eBike, General Electric Healthcare, Bedford, UK) with 
expired gas analysis (Ganshorn PowerCube, General 
Electric Healthcare, Bedford, UK) to determine peak 
oxygen consumption (oxygen consumption (VO2)), the 
gold standard assessment of cardiovascular fitness.52
Randomisation
Participants will undergo randomisation at the baseline 
visit, using an independent online computerised rando-
misation system (Sealed Envelope). Randomisation will be 
stratified by sex, given different LV remodelling processes 
in men and women,53 and by baseline glucose-lowering 
therapy (any glucagon-like peptide-1, dipeptidyl pepti-
dase-IV or sodium glucose cotransporter 2 inhibitor vs 
none of these).
Study interventions
Recruited participants will be randomised to one of three 
groups: (1) standard of care as per National Institute for 
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
 ► Capacity to provide informed consent before any trial-
related activities.
 ► Established T2D (≥3 months).
 ► HbA1c ≤9% if on triple therapy or ≤10% on diet and 
exercise or monotherapy or dual therapy.
 ► Current glucose-lowering therapy either mono, dual or triple 
of any combination of metformin, sulphonylurea, DPP-IV 
inhibitor, GLP-1 therapy or an SGLT2i±diet and exercise.
 ► Poorly managed diet controlled diabetes (with 
HbA1c >6.5%, not currently taking any glucose-lowering 
therapy, meeting BMI inclusion range).
 ► BMI >30 kg/m2 or >27 kg/m2 (South Asian).
 ► Diagnosis of T2D before the age of 60 years of age.
 ► Age ≥18 and ≤65 years.
 ► Diabetes duration >12 years.
 ► Currently taking more than three glucose-lowering 
therapies.
 ► Weight loss of >5 kg in the preceding 6 months.
 ► Stage 4 or 5 chronic kidney disease (eGFR <30 mL/
min/1.73 m2).
 ► Current therapy with insulin, thiazolidinediones, steroids or 
atypical antipsychotic medication.
 ► Untreated thyroid disease.
 ► Known macrovascular disease including coronary artery 
disease, stroke/TIA or peripheral vascular disease.
 ► Presence of arrhythmia (including atrial fibrillation, atrial 
flutter or second or third degree atrioventricular block).
 ► Known heart failure or other clinically relevant heart disease.
 ► Inability to exercise or undertake a MRP.
 ► Absolute contraindication to CMRI.
 ► Cardiovascular symptoms (angina and limiting dyspnoea 
during normal physical activity).
 ► Inflammatory condition, for example, connective tissue 
disorder and rheumatoid arthritis.
BMI, body mass index; CMRI, cardiovascular MRI; DPP-IV, dipeptidyl peptidase-IV inhibitor; eGFR, estimated glomerular filtration rate; 
GLP-1, glucagon-like peptide 1; MRP, meal replacement plan; SGLT2i, sodium glucose cotransporter 2 inhibitor; T2D, type 2 diabetes; TIA, 
transient ischaemic attack.
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Health and Care Excellence guidance54 including life-
style advice, (2) MRP or (3) supervised exercise training.
1. The standard care group will be provided with stan-
dard lifestyle advice according to National Institute for 
Health and Care Excellence guidance,55 delivered in a 
single health coaching interview at week 0. This lifestyle 
advice will be reinforced at the week 12 assessment.
2. The MRP group will receive a low-energy MRP diet 
containing an average of ≈810 kcal/day (30% protein, 
50% carbohydrate, 20% fat) (Cambridge Weight Plan). 
This diet plan complies with all current guidance 
and government legislation (European Food Safety 
Authority) for macronutrient and micronutrient content 
and quality.56 Participants randomised to the MRP group 
will be asked to discontinue all glucose-lowering therapies 
following randomisation to avoid hypoglycaemia. Antihy-
pertensive drugs will be stopped on the day of low-energy 
diet commencement, as a safety measure because blood 
pressure is likely to fall substantially (mean drop in systolic 
blood pressure ~20 mm Hg) on the diet.35 Any alterations 
to medication will ultimately be made at the discretion 
of the study clinician(s). The clinical team will include 
specialists in CVD and diabetes medicine to oversee alter-
ations in antihypertensive and glucose-lowering therapy. 
Figure 1 Study overview. CMR, cardiac MRI; CPET, cardiopulmonary exercise testing; MRP, meal replacement plan MRP.
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Blood pressure and glucose will be monitored throughout 
the study at the clinical review sessions (see below).
The MRP will be undertaken alongside health behaviour 
coaching and relapse prevention through weekly contact, 
where possible, with a qualified dietician or equivalent. 
Participants will be asked to maintain their usual daily 
activities and not initiate any additional physical activity 
for the duration of the study. Those participants in the 
MRP arm who do not achieve a loss of >2% body weight 
at week 1 and 4% at week 3 will be considered non-com-
pliant and excluded from the study. Investigator discre-
tion will be used when considering non-compliance in 
the event of borderline values. The diet will be stopped, 
and a maintenance diet reintroduced once 50% excess 
body weight has been lost, or by 12 weeks, whichever 
comes first. The maintenance diet will be individualised 
and agreed with the participant, based on their estimated 
total energy expenditure at that point. The self-reported 
intake at week 12 will be recorded and comparisons made 
between arms for macronutrient and energy intake.
3. The exercise group will attend supervised sessions at 
the Leicester Biomedical Research Centre. The exercise 
programme will be undertaken thrice weekly, progressing 
to 50 min per session of moderate intensity aerobic exer-
cise, in line with prevailing guidelines (150 min per week). 
Each exercise session will consist of a warm-up, stimulus 
and cool-down phase. Static stretching will be undertaken 
at the end of each session. The stimulus phase will include 
walking and/or lower extremity cycling. The duration of 
exercise in each training mode will also be increased grad-
ually to achieve the 50 min target. An initial assessment of 
cardiorespiratory fitness will be performed, and exercise 
intensity titrated using the value from the baseline peak 
VO2 assessment. Objective (heart rate monitoring) and 
subjective (Borg Rate of Perceived Exertion Scale, graded 
from 6 to 20) measures will be used to measure responses 
to the exercise sessions with exercise intensity adjusted 
progressively to take account of increasing fitness levels 
throughout the intervention period as follows:
Weeks 1 and 2: 15 min at ~50% peak VO2.
Week 3: 25 min at ~60% peak VO2.
Week 4: 30 min at ~60% peak VO2.
Week 5: 35 min at ~60% peak VO2.
Week 6: 40 min at ~60% peak VO2.
Week 7: 45 min at ~60% peak VO2.
Weeks 8–12: 50 min at ~60% peak VO2.
Although weight loss may occur in the exercise group, 
this is not the main aim of the intervention, which is to 
assess whether diastolic function improves independent 
of weight loss. Compliance will be assessed by attendance 
at the supervised sessions. Patients in the exercise arm 
who attend less than two-thirds of the supervised sessions 
in the first 4 weeks and then throughout the remainder of 
the study period will be excluded. Investigator discretion 
may be used in cases where compliance is borderline.
Participants will be asked to maintain their usual dietary 
intake, and a self-reported food diary will be applied 
before and after the intervention to estimate intake. 
Participants in the exercise arm will have their medication 
reviewed by the study clinician at baseline. Those with an 
HbA1c ≤8% who are currently taking a sulphonylurea will 
initially have the dose reduced by 50% 72 hours prior to 
the first exercise session. Their regimes will be continued 
to be down-titrated starting with the sulphonylurea 
and then moving, where applicable, onto their current 
sodium glucose cotransporter-2 inhibitor or dipeptidyl 
peptidase-IV inhibitor or glucagon-like peptide-1 thera-
pies according to glycaemic control. The latter therapies 
will be titrated down last given their relative low risk of 
hypoglycaemic events. For those participants with an 
HbA1c ≤8% who are not taking a sulphonylurea, the 
study clinician will down-titrate glucose-lowering therapy 
on an individual basis, taking into account the class and 
combination of therapies prescribed. All other medica-
tion will be maintained unless the study clinician deems 
alterations are necessary for a patient’s best interest. 
Alterations in medication will be supervised by clinicians 
specialised in diabetes medicine.
Subsequent clinical reviews
All participants will have an initial clinical review postran-
domisation at the time of their health coaching. In order 
to ensure their continued safety, each participant in the 
MRP or exercise arm will be invited for frequent clinical 
reviews. They will attend six reviews after randomisation 
in total (weeks 1, 2, 4, 6, 8 and 12), as well as receiving a 
telephone consultation at weeks 3 and 10. At these clin-
ical reviews their blood pressure, fasting glucose (weeks 1, 
2 and 4 for MRP arm) and weight will be measured. This 
is to inform: (A) any additional alterations to medication 
that need to be made and (B) compliance to the MRP 
and exercise programme as appropriate.
Optional 4-week visit
The 4-week assessment is optional and will only be 
conducted on a subset of participants who provide addi-
tional consent. Measures taken during the baseline visit 
will be repeated to ascertain whether there are early alter-
ations to outcome measures in participants randomised 
to the study interventions.
Twelve-week final data collection visit
All measures and tests undertaken at the baseline visit 
will be repeated at the 12-week final data collection visit. 
Participants will undergo one further clinical review (see 
above) following the 12-week data collection visit, which 
will be the final visit and the end of the study. Medica-
tions will be reviewed, and any medication reintroduced 
will be tailored to the individual based on previous and 
current HbA1c and blood pressures. This review will be 
undertaken by an experienced study clinician and the 
outcome communicated to the patient’s usual physician 
and general practitioner.
Blood glucose monitoring
Participants in both intervention arms (MRP and exer-
cise) will be provided with blood glucose monitoring 
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equipment to capture seven-point glucose profiles across 
key time-points during the study (prior to initial consulta-
tion week 0, prior to the 4-week visit and prior to 12-week 
visit), which will be recorded in a blood glucose moni-
toring diary and/or via direct download of the blood 
glucose metre data at the end of the study where possible. 
It will also allow them to self-monitor their glucose levels 
through the study and capture any hypoglycaemic events 
to guide medication adjustments accordingly if required. 
Additionally, hyperglycaemia will be assessed, and medi-
cation adjusted if necessary after review of compliance to 
intervention. These will be self-reported by the partici-
pant in the blood glucose monitoring diary.
Magnetic resonance imaging
Reproducibility of PEDSR appears to be better at 1.5T than 
at 3T, and therefore, 1.5T is our preferred field strength 
for CMR assessment of diastolic function.57 Myocardial 
triglyceride on the other hand is measured using magnetic 
resonance spectroscopy, a technique generally considered 
to be best performed at 3T, due to the higher signal to noise 
ratio compared with 1.5T.58 We will therefore perform 
magnetic resonance spectroscopy on a 3T scanner (Skyra, 
Siemens, Erlangen), with all other MRI data being collected 
on a 1.5T scanner (Aera, Siemens, Erlangen).
The MRI protocol is outlined in figure 2 and is similar 
to that described previously.59 An exception to this is that 
myocardial tissue tagging and T1 mapping have been 
omitted. Myocardial tissue tagging requires the acquisition 
of additional images with long breath hold duration and 
is time consuming to analyse. Alternatives include phase 
velocity mapping, displacement encoding with simulated 
echoes and strain-encoded images, all of which require the 
acquisition of additional sequences and/or involve lengthy 
postprocessing times.60 Instead, we will use tissue tracking 
of balanced steady-state free precession LV cine images, 
which has emerged as a reliable alternative technique for 
the assessment of strain and diastolic strain rate57 61 62 with 
good test-test reproducibility for PEDSR in our lab.56
Briefly, after localisers, Dixon gradient echo pulse 
sequences covering the thorax and abdomen will be 
acquired for thoracic and abdominal subcutaneous and 
visceral fat. Liver triglyceride content will also be assessed 
by HepaFat-Scan, which has been validated against stere-
ological analysis of liver biopsy sections for measure-
ment of liver fat fraction.63 Steady-state free precession 
cine images will be acquired in four-chamber, three-
chamber and two-chamber views. Perfusion images will 
be acquired after pharmacological vasodilation with 
adenosine (140 µg/kg/min, for 2–3 min) until a haemo-
dynamic response is achieved (a drop in systolic blood 
pressure of 10 mm Hg and/or rise in heart rate of 10 
bpm). During peak stress, a gadolinium-based contrast 
agent (Gadoterate meglumine, Dotarem, Guerbet LLC, 
France) will be injected (0.04 mmol/kg), followed by a 
20 mL bolus of normal saline, at a rate of 5 mL/s, and 
perfusion images will be acquired using a saturation 
recovery gradient echo pulse sequence for three slices 
(basal, mid and apical). Rest imaging will be performed 
approximately 10 min after stress imaging with a further 
0.04 mmol/kg of contrast. In the intervening time, a stack 
of short-axis slices will be obtained using cine images 
covering the entire LV. A further 0.07 mmol/kg top-up of 
contrast will be administered to bring the total contrast 
dose to 0.15 mmol/kg. Aortic cine images will be acquired 
in a plane perpendicular to the thoracic aorta at the level 
of the pulmonary artery bifurcation. Through-plane 
phase contrast sequences perpendicular to the ascending 
and descending aorta at the level of the pulmonary bifur-
cation will be captured for pulse wave flow analysis. To 
determine the aortic arch segment length between which 
aortic pulse wave velocity is calculated, sagittal oblique 
aortic cine images will be acquired. At least 10 min after 
top-up contrast administration, late gadolinium enhance-
ment images will be obtained with an inversion-recovery 
prepared, segmented gradient echo sequence.
CMrI analysis
Scans will be anonymised and sent to a standalone work-
station for blinded analysis as previously described.19 
Briefly systolic strain and longitudinal PEDSR will be 
quantified from cine images using tissue tracking. LV 
volumes, mass and function will be calculated using 
commercially available software (cmr42, Circle Cardiovas-
cular Imaging, Calgary, Canada). Myocardial strain will 
be measured using both Image Arena Feature Tracking 
(TomTec Imaging Systems, Unterschleissheim, Germany) 
and cmr42 Tissue Tracking (Circle Cardiovascular 
Imaging). Interobserver and intraobserver variability 
will be calculated on at least 10 random datasets by two 
experiences observers and results reported. Test–retest 
reproducibility will be assessed for the primary endpoint 
in 10 subjects and the analysis technique that has the 
best reproducibility will be used for the final analysis, 
and if they have similar reproducibility, we will use tissue 
tracking since this can be generated using the contours 
drawn for LV mass analysis. The epicardium and endocar-
dium will be contoured on the perfusion images, along 
with a region of interest in the LV blood pool to generate 
signal intensity curves. Myocardial perfusion reserve will 
be calculated using Fermi-constrained deconvolution as 
previously described.19 Late gadolinium enhancement 
will be assessed qualitatively as absent or present and 
quantified by a thresholding technique >5 SDS above 
remote normal myocardium.64
transthoracic echocardiography
Comprehensive transthoracic echocardiography will be 
performed according to British Society of Echocardiog-
raphy guidelines.65 Each participant will have assessment 
for: tissue Doppler indices of diastolic filling and speckle 
tracking for systolic and diastolic strain/strain rate, exclu-
sion of valvular abnormalities, assessment of LV size and 
function. Given the difficulties in grading diastolic dysfunc-
tion in mild and moderate disease,66 the primary focus on 
echocardiography will be on E/e′, a non-invasive surrogate 
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of LV filling pressure.67 Mitral annular velocities (e′) will 
also be reported to account for the possibility that enlarged 
left atrial volumes may result in a decreased E wave velocity 
and apparent reduction of E/e′ in people with diabetes.68
study outcomes
Primary outcome
The primary outcome measure is change in circumfer-
ential PEDSR, measured by CMR from baseline to 12 
weeks. Other measures of cardiac structure and function 
assessed in the study are shown in box 1.
secondary outcomes
Anthropometric variables
Body weight, height, hip and waist circumference will 
be measured to the nearest 0.1 kg, 1 cm, 1 cm and 1 cm, 
respectively. Waist circumference will be measured using 
a soft tape with the participant standing, feet together, 
at the level of the umbilicus. Hip circumference will be 
measured at the level of the greater trochanters. Brachial 
blood pressure will be obtained from the seated partici-
pant’s dominant arm. Three measurements will be taken 
Figure 2 1.5 Tesla CMR protocol for covering thoracic and abdominal subcutaneous and visceral fat (Dixon) function (cine), 
arterial stiffness and late gadolinium enhancement for focal fibrosis. CMR, cardiac MRI; LA, left atrium; LGE, late gadolinium 
enhancement; LV, left ventricle; SAO, sagittal oblique.
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and an average of the last two measurements will be used. 
Ethnicity, smoking status, medical history and medica-
tions history will be obtained by self-report.
Biochemical variables
Standard biochemical outcomes will be assessed by venous 
blood sampling. These will include fasting glucose and 
HbA1c, lipid profile (fasting triglycerides, HDL, low-den-
sity lipoprotein and total cholesterol), urea and electro-
lytes (sodium, potassium, urea and creatinine) and liver 
function tests (albumin, total bilirubin, alkaline phos-
phatase and alanine transaminase). Postmeal increase of 
glucose and absolute values of postmeal glucose will be 
assessed from the seven-point glucose profile.
Cardiovascular fitness
Participants will undergo a maximum incremental exer-
cise test on a stationary bicycle (electromagnetically 
braked cycle ergometer) with expired gas analysis to 
determine peak VO2. The exercise test will begin with 
a 3 min warm-up phase and end with a 3 min cool-down 
phase. One-minute workload increments will be based on 
patient age, gender, height and weight.52 The test will be 
physician supervised, and blood pressure will be recording 
at 2 min intervals. Indications for medical termination will 
be as previously described.69 A quality control cardiopul-
monary exercise test is undertaken every 6 weeks using a 
biological control in our unit. The coefficient of variation 
for VO2 (L/min) during steady state at workloads of 75, 
100, 125 and 150 watts is consistently <8%.
Recent Physical Activity Questionnaire
Self-reported physical activity will be measured using 
the Recent Physical Activity Questionnaire as previously 
described.70 This assesses physical activity across four 
domains (domestic, recreational, occupational and 
commuting) over the previous month. The Recent Phys-
ical Activity Questionnaire has been shown to be a reli-
able and valid tool for measuring physical activity.71
Accelerometer
Participants will be asked to wear the accelerometer on 
a waistband (in the right anterior axillary line) during 
waking hours for seven consecutive days. A log sheet is 
provided for participants to record each day that they 
wear the accelerometer and document when the accel-
erometer was removed at night, time they went to sleep, 
time they woke up and time the accelerometer was reat-
tached. Participants will return the accelerometer and log 
sheet via prepaid envelope at the end of 7 days of wear. A 
minimum of 3 days valid wear will be required to count as 
a valid recording. Raw acceleration data are captured and 
stored at 100 Hz. Data processing will be undertaken on 
commercially available analysis software.
Dual-energy X-ray absorptiometry
Each participant will undergo a DEXA scan using a total-
body scanner. DEXA uses a technology by which the radi-
ation at two energies is used to determine components of 
the attenuating tissue, either bone and soft tissue or lean 
soft tissue and fat. DEXA has been validated as a measure 
of body fat in obese and normal weight individuals72 73 
and as such is considered to be one of the gold standard 
measurements for determining body composition.
Estimates of total and regional fat mass and fat free mass 
will be automatically derived using the iDEXA encore soft-
ware. Areas of particular interest include the appendages 
and trunk (encompassing android and gynoid regions). 
Daily quality assurance and quality controls will be carried 
out during the study period according to standard proce-
dures supplied by the manufacturer. The volunteers 
will be scanned using standard imaging and positioning 
protocols.
statistical analyses
Sample sizes
The power calculation is based on the previously 
mentioned pilot study from our group.19 The patients 
with T2D had a circumferential PEDSR of  1.5
1
s   with SD 
of  0.2
1
s  . Based on this, 30 patients per group will have 
80% power to detect a between group difference in 
PEDSR of  0.2
1
s   assuming alpha=0.025 (to allow for two 
primary comparisons, ie, MRP vs standard care and exer-
cise vs standard care) and a maximum 30% dropout.29 30 
Such an improvement would result in a strain rate  (1.7
1
s )  
similar to that seen in the obese controls  (1.8
1
s )  but still 
lower than the lean controls  (2.0
1
s ) .
Statistical methods and analyses
The aim of these analyses is to compare the change in 
primary outcome (PEDSR) at 12 weeks between the 
MRP and standard care arms, and between the exercise 
and standard care arms. The primary analysis will be 
a complete case analysis as this is a proof of principle 
study where we are primarily interested in the size of 
box 1 key imaging outcome measures
Primary outcome measures
 ► Change in circumferential PEDSR measured from baseline to 
12 weeks.
secondary outcome measures
 ► Longitudinal PEDSR.
 ► Standard assessments of structure and function (eg, LV mass, 
end-diastolic/systolic volumes, mass/volume and ejection fraction).
 ► Left atrial volumes.
 ► Myocardial systolic strain/strain rates (circumferential and 
longitudinal).
 ► Arterial stiffness (mean ascending and descending aortic distensi-
bility and pulse-wave velocity).
 ► Global myocardial perfusion reserve as a marker of microvascular 
function.
 ► Myocardial and liver triglyceride content.
 ► Echocardiographic mitral inflow velocity (E), myocardial relaxation 
(E′) and E/E′, a non-invasive marker of LV filling pressure. Diastolic 
dysfunction will be graded.
LV, left ventricular; PEDSR, peak early diastolic strain rate.
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the treatment effect, rather than the practicability of the 
intervention. A CONSORT diagram will be produced. 
At baseline and each follow-up, descriptive variables 
and changes in outcomes will be summarised by arm 
using mean (SD) for normally distributed continuous 
variables, median (IQR) for non-normally distributed 
continuous variables and count (percentage) for categor-
ical variables. Each intervention will be compared with 
the control group (ie, MRP vs standard care and exer-
cise vs standard care) using linear regression adjusted 
for stratification factors and baseline values. The exercise 
and MRP arms will be compared as a secondary analysis. 
If necessary, the outcome variable will be appropriately 
transformed so that the assumptions of the linear regres-
sion model are held. Intention-to-treat analyses will be 
performed as sensitivity analyses using multiple imputa-
tion or another appropriate approach to impute missing 
data.
Patient and public involvement (PPI)
The University of Leicester and the Leicester NIHR 
Biomedical Research Centre have very active PPI groups 
in both diabetes and cardiovascular sciences. The study 
outline was presented to our PPI groups for feedback 
prior to designing the study protocol. In addition, PPI 
focus groups were held about the study design and 
conduct before the protocol was finalised. In particular, 
the PPI groups assessed the burden of the exercise and 
acceptability of the MRP arms on study participants 
to ensure appropriate support was available to help 
compliance with these interventions. Furthermore, the 
trial steering committee (see below) has at least two 
lay members for study oversight. All study participants 
and members of the public will be invited to return 
for a lecture disseminating the study’s key findings on 
completion.
Trial oversight and governance
The study sponsor is the University of Leicester and is 
managed by the Leicester Clinical Trials Unit (CTU) and 
is overseen by the trial steering committee composed of 
an independent chair and a group of experts. The inde-
pendent chair of the trial steering committee is Professor 
Roy Taylor, professor of medicine and metabolism and 
director of the Magnetic Resonance Centre, Newcastle 
University. This study is registered on http://www. clini-
caltrials. gov and monitored by the University of Leicester. 
Data completeness and quality is reviewed by the Leicester 
CTU. The quality of 10 randomly selected baseline MRI 
datasets was assessed by an independent laboratory 
(Professor Sven Plein, Leeds, UK) and all images were 
graded as excellent or good.
Given the open design of the study, it was determined 
that a data monitoring and ethics committee was not 
required. All serious adverse events are reported to the 
sponsor according to current guidelines and the trial 
steering committee.
Current status and timescale
Recruitment started in January 2016 and follow-up of the 
last participant was completed by end of August 2018.
dIsCussIon
Younger adults with T2D are at very high lifetime risk of 
developing HF. Concentric LV remodelling with asso-
ciated diastolic dysfunction appears to be the earliest 
manifestation of diabetic cardiomyopathy. The occur-
rence of diastolic dysfunction reflects abnormal LV relax-
ation and increased LV stiffness and has been shown to 
predict an increased risk of developing overt HF within 
5 years.74 Reported prevalence rates of diastolic dysfunc-
tion in asymptomatic patients with T2D are as high as 
78%.75 Therapies that may reverse diastolic dysfunction 
or prevent progression to overt chronic HF are therefore 
urgently needed.
In the DiRECT study delivered in primary care, an 
MRP programme led to an average weight loss of 10 kg 
and remission of diabetes in 46% of overweight or obese 
patients with T2D.27 The cardiovascular benefits of weight 
loss, however, are less well characterised in T2D, although 
a reduction in myocardial steatosis and improved 
diastolic filling has been shown with a VLED in T2D.35 A 
more substantial body of evidence exists for the beneficial 
cardiovascular effects of weight loss in obese non-diabetic 
subjects including: reductions in mass/volume, improved 
diastolic dysfunction and arterial stiffness.33 76
Similarly, exercise training has favourable effects 
on glycaemic control and cardiovascular outcomes in 
T2D.38–41 These benefits of exercise training appear inde-
pendent of weight loss, suggesting that the underlying 
mechanisms are different.40 41 However, data supporting 
positive effects of exercise training on diastolic dysfunc-
tion in T2D are lacking, although reversal of diastolic 
dysfunction with exercise has been demonstrated in 
subjects with obesity.44 This study will be among the first 
to compare and establish the effects of weight loss and 
exercise on cardiac structure and function in younger 
adults with T2D. If either of these interventions were to 
successfully reduce diastolic dysfunction, it is likely that 
the outcome will contribute to national and international 
guidelines in this area.
other interventions that may improve diastolic dysfunction
Newer glucose-lowering therapies may improve cardio-
vascular (CV) outcomes in patients with T2D. Sodium 
glucose cotransport-2 inhibitors reduce the risk of HF and 
glucagon-like peptide-1 receptor agonists lower throm-
botic events,77 but for optimum benefit, they will require 
to be used in conjunction with lifestyle interventions, 
which may actually modify the underlying pathophysio-
logical process of T2D development. Similarly, intensive 
blood pressure lowering may or may not improve CV 
outcomes in patients with T2D, but there are inconsisten-
cies in the recommended blood pressure targets.55 78 79 
Current National Institute for Health and Care Excellence 
M
edical Library. Protected by copyright.
 o
n
 February 14, 2020 at Assistant Librarian St Jam
es`s Hospital
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023207 on 30 March 2019. Downloaded from 
11Gulsin GS, et al. BMJ Open 2019;9:e023207. doi:10.1136/bmjopen-2018-023207
Open access
(NG28) recommendations are that blood pressure be 
maintained below 140/80 mm Hg in uncomplicated T2D 
or below 130/80 mm Hg if there is a history of kidney, 
eye or cerebrovascular disease.55 Importantly, both MRP 
diets31 35 and exercise80 81 have favourable effects on blood 
pressure, supporting these strategies as interventions for 
CV risk reduction in T2D.
limitations
This is a proof-of-efficacy study and therefore effects on 
clinical outcomes are not planned with a short dura-
tion of follow-up. Only patients who are able to exercise 
and willing to undertake the MRP are eligible, and we 
have limited our inclusion to younger adults (<65 years) 
with a maximum duration of diabetes of 12 years, so the 
results will not necessarily be generalisable to all people 
with T2D. The study interventions, given their nature, 
are not blinded, but ascertainment bias is limited by the 
blinded assessment of the primary outcome and other 
imaging parameters. Only the core lab is performing 
the quantitative analysis of blinded images, and we will 
not request that another laboratory performs indepen-
dent segmentation analysis for evaluation of interlab-
oratory variation. However, a subset of 10 randomly 
selected CMR datasets was reviewed by an internation-
ally regarded independent expert (Professor Sven Plein, 
Leeds, UK) to assure data quality and integrity. A small-
er-than-expected treatment effect in the intervention 
arms of the study could render the study underpowered, 
although the current dropout rate is closer to 20% than 
the allowed for 30%. The participants in the interven-
tion arms receive increased contact with study investiga-
tors that will only partially be offset by health coaching 
that is administered at baseline to the control group. 
Follow-up of the last participant recruited to the study 
was completed by the end of August 2018, which limits 
changes to data collection.
declarations
Ethics and dissemination
The study is conducted in accordance with the principles 
of the 1996 Helsinki Declarations, International Confer-
ence on Harmonisation-Good Cinical Practice (ICH-
GCP) guidelines. It is anticipated that data collection 
will be completed by end of August 2018, and the study 
results will be submitted for publication within 6 months 
of completion.
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